US Patent 10098968 Anti-EGFR antibodies and antibody drug conjugates
Patent 10098968 was granted and assigned to AbbVie Inc. on October, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+193 characters)
Article
Patent abstract
The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Edits on 20 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 30 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100989680
Date of Patent
October 16, 2018
0Patent Application Number
158084190
Date Filed
November 9, 2017
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100989680
Date of Patent
October 16, 2018
0Patent Application Number
158084190
Date Filed
November 9, 2017
0Patent Primary Examiner
Edits on 22 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10098968 Anti-EGFR antibodies and antibody drug conjugates
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10098968
Date of patent
October 16, 2018
Patent application number
15808419
Date Filed
November 9, 2017
Patent primary examiner
Find more entities like US Patent 10098968 Anti-EGFR antibodies and antibody drug conjugates
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
